MCID: THY124
MIFTS: 52

Thyroid Gland Papillary Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Papillary Carcinoma

MalaCards integrated aliases for Thyroid Gland Papillary Carcinoma:

Name: Thyroid Gland Papillary Carcinoma 12
Papillary Carcinoma of the Thyroid Gland 12
Papillary Thyroid Carcinoma 15

Classifications:



External Ids:

Disease Ontology 12 DOID:3969
MeSH 43 C536915
NCIt 49 C4035
SNOMED-CT 67 4797003
UMLS 71 C0238463

Summaries for Thyroid Gland Papillary Carcinoma

Disease Ontology : 12 A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer abd arises from the follicular cells of the thyroid gland.

MalaCards based summary : Thyroid Gland Papillary Carcinoma, also known as papillary carcinoma of the thyroid gland, is related to multicentric papillary thyroid carcinoma and tall cell variant papillary carcinoma. An important gene associated with Thyroid Gland Papillary Carcinoma is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Iodine and Micronutrients have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast.

Related Diseases for Thyroid Gland Papillary Carcinoma

Diseases related to Thyroid Gland Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 528)
# Related Disease Score Top Affiliating Genes
1 multicentric papillary thyroid carcinoma 33.3 TG RET
2 tall cell variant papillary carcinoma 33.2 TG RET
3 nodular goiter 32.0 TG RET MIR199A1
4 struma ovarii 31.7 TG RET
5 thyroid gland anaplastic carcinoma 31.7 TG RET MIR30A MIR17
6 thyroid gland follicular carcinoma 31.5 TG RET MIR9-1 MIR222 MIR183 MIR144
7 malignant struma ovarii 31.3 TG RET
8 ovarian germ cell teratoma 31.3 TG RET
9 thyroid gland medullary carcinoma 31.0 TG RET MIR183
10 nonencapsulated sclerosing carcinoma 30.9 TG RET
11 thyroid cancer, nonmedullary, 1 30.9 MIR222 MIR221 MIR146A
12 follicular adenoma 30.8 TG RET MIR221
13 multinodular goiter 30.8 TG MIRLET7E MIR222
14 benign struma ovarii 30.7 TG RET
15 diffuse large b-cell lymphoma 30.7 MIRLET7E MIR222 MIR221 MIR199A1 MIR181A1 MIR17
16 bone inflammation disease 30.6 MIR30A MIR199A1 MIR17 MIR146A MIR140
17 melanoma 30.6 MIRLET7E MIR222 MIR221 MIR183 MIR181A1 MIR17
18 inherited metabolic disorder 30.5 MIR9-1 MIR199A1 MIR17 MIR144
19 glioma susceptibility 1 30.5 MIR486-1 MIR25 MIR222 MIR221
20 leukemia, acute lymphoblastic 30.4 MIRLET7E MIR9-1 MIR222 MIR221 MIR17 MIR130B
21 glioma 30.4 MIR25 MIR222 MIR221 MIR17 MIR146B MIR140
22 renal cell carcinoma, nonpapillary 30.4 RET MIR9-1 MIR486-1 MIR30A MIR221 MIR199A1
23 pancreatic ductal adenocarcinoma 30.3 MIR222 MIR221 MIR199A1 MIR183 MIR146A MIR130B
24 autosomal genetic disease 30.2 RET MIR9-1 MIR486-1 MIR199A1 MIR181A1 MIR17
25 esophageal cancer 30.1 MIR9-1 MIR486-1 MIR30A MIR199A1 MIR146A MIR144
26 oral squamous cell carcinoma 30.0 MIRLET7E MIR9-1 MIR221 MIR199A1 MIR181A1 MIR17
27 thyroid gland cancer 30.0 TG RET MIRLET7E MIR9-1 MIR574 MIR499A
28 leukemia, chronic lymphocytic 30.0 MIR9-1 MIR574 MIR486-1 MIR30A MIR221 MIR199A1
29 gastric cancer 30.0 MIR9-1 MIR25 MIR222 MIR221 MIR199A1 MIR17
30 lung cancer susceptibility 3 29.9 RET MIRLET7E MIR9-1 MIR574 MIR486-1 MIR30A
31 colorectal cancer 29.8 RET MIR9-1 MIR30A MIR25 MIR221 MIR199A1
32 connective tissue disease 29.8 MIR9-1 MIR486-1 MIR30A MIR222 MIR221 MIR199A1
33 colonic disease 29.8 MIR9-1 MIR574 MIR486-1 MIR30A MIR25 MIR221
34 squamous cell carcinoma, head and neck 29.7 MIRLET7E MIR9-1 MIR574 MIR486-1 MIR30A MIR221
35 bladder cancer 29.7 MIR9-1 MIR222 MIR221 MIR17 MIR146A MIR144
36 ovarian cancer 29.6 MIRLET7E MIR9-1 MIR30A MIR25 MIR222 MIR221
37 leukemia, acute myeloid 29.6 MIRLET7E MIR9-1 MIR574 MIR486-1 MIR30A MIR222
38 endocrine gland cancer 29.3 RET MIR9-1 MIR574 MIR486-1 MIR30A MIR25
39 hepatocellular carcinoma 29.3 MIRLET7E MIR9-1 MIR30A MIR25 MIR222 MIR221
40 thyroid gland disease 29.1 TG RET MIRLET7E MIR9-1 MIR574 MIR486-1
41 lung cancer 28.8 RET MIRLET7E MIR9-1 MIR574 MIR499A MIR486-1
42 thyroid carcinoma, papillary, with papillary renal neoplasia 11.7
43 columnar cell variant papillary carcinoma 11.5
44 thyroid cancer, nonmedullary, 4 11.4
45 hashimoto thyroiditis 10.7
46 familial adenomatous polyposis 10.7
47 thyroid cancer, nonmedullary, 2 10.7
48 papillary thyroid microcarcinoma 10.6
49 graves' disease 10.6
50 hyperparathyroidism 10.6

Graphical network of the top 20 diseases related to Thyroid Gland Papillary Carcinoma:



Diseases related to Thyroid Gland Papillary Carcinoma

Symptoms & Phenotypes for Thyroid Gland Papillary Carcinoma

Drugs & Therapeutics for Thyroid Gland Papillary Carcinoma

Drugs for Thyroid Gland Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3 7553-56-2 807
2 Micronutrients Phase 2, Phase 3
3 Trace Elements Phase 2, Phase 3
4 Nutrients Phase 2, Phase 3
5 Anti-Infective Agents Phase 2, Phase 3
6 cadexomer iodine Phase 2, Phase 3
7 Anti-Infective Agents, Local Phase 2, Phase 3
8
Calcium carbonate Approved, Investigational Phase 2 471-34-1
9
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
10
Lenvatinib Approved, Investigational Phase 2 417716-92-8
11
Pembrolizumab Approved Phase 2 1374853-91-4
12
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
13
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
14
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
15
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
16
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
17
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181
18 Liver Extracts Phase 2
19 Vitamins Phase 2
20 Hormones Phase 2
21 Gastrointestinal Agents Phase 2
22 Hydroxycholecalciferols Phase 2
23 Ergocalciferols Phase 2
24 Anti-Ulcer Agents Phase 2
25 Calcium, Dietary Phase 2
26 Calciferol Phase 2
27 Vitamin D2 Phase 2
28 Antacids Phase 2
29 Antineoplastic Agents, Immunological Phase 2
30 Protein Kinase Inhibitors Phase 2
31 Fluorodeoxyglucose F18 Phase 2
32 Radiopharmaceuticals Phase 2
33
Dabrafenib Approved, Investigational Phase 1 1195765-45-7 44462760 44516822
34 Anti-Inflammatory Agents
35 Antiviral Agents
36 Antimetabolites
37 Anesthetics
38 Deoxyglucose
39 Antibodies
40 Immunologic Factors
41 Immunoglobulins

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
2 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
4 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
5 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
6 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
7 Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients Completed NCT00630214 Phase 2
8 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
9 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
10 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
11 A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Completed NCT01813136 Phase 2 Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B)
12 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Recruiting NCT02973997 Phase 2 Lenvatinib
13 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
14 Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumors Active, not recruiting NCT01677741 Phase 1 Dabrafenib
15 Differences Protein Expression in Papillary Thyroid Carcinoma Unknown status NCT02814032
16 Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma Unknown status NCT01417442 Early Phase 1
17 99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study Unknown status NCT00984191
18 Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound Unknown status NCT00929318
19 Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules Unknown status NCT03309631
20 Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report. Unknown status NCT01075269
21 Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial Unknown status NCT02140476
22 The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis Completed NCT01103557
23 Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma Completed NCT00459459
24 Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC Completed NCT02561533
25 Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy Completed NCT01354639
26 Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls Completed NCT01659385
27 APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. Completed NCT02323724
28 A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction Completed NCT01311089
29 Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 Completed NCT01534897 GSK2118436
30 Sentinel Node Investigation in Patients With Highly Differentiated Papillary Thyroid Carcinoma and in Patients With Thyroid Neoplasia of Unclear Malignant Potential Completed NCT01089335
31 Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy Completed NCT02347683
32 Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? Completed NCT00439127
33 The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma Recruiting NCT04076514
34 The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma Recruiting NCT02418390
35 A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated Recruiting NCT02776969
36 Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma Recruiting NCT03889769
37 From the Endoscope to the Robot, the Initial Experience of Robotic Thyroidectomy is Summarized Recruiting NCT03454477
38 Active Surveillance of Papillary Thyroid Microcarcinoma Recruiting NCT02609685
39 Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer Recruiting NCT03830242
40 Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation Not yet recruiting NCT04129411
41 A Prospective Multicenter Study to Compare the Therapeutic Outcomes of Microwave Ablation With Surgical Resection for Micropapillary Thyroid Carcinoma Not yet recruiting NCT04197960
42 Prospective Study for the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma Not yet recruiting NCT03813706
43 Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma: a Prospective Study Not yet recruiting NCT03813173
44 Role of of F-18-fluoro-deoxy-glucose (FDG) PET/CT in Thyroid Cancer Patients With Negative I-131whole Body Scan and Elevated Thyroglobulin Level or Positive Anti Thyroglobulin Antibodies Not yet recruiting NCT04128631
45 A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC) Suspended NCT03327636
46 Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial Terminated NCT01106443

Search NIH Clinical Center for Thyroid Gland Papillary Carcinoma

Genetic Tests for Thyroid Gland Papillary Carcinoma

Anatomical Context for Thyroid Gland Papillary Carcinoma

MalaCards organs/tissues related to Thyroid Gland Papillary Carcinoma:

40
Thyroid, Lymph Node, Breast, Lung, Bone, Pituitary, Testes

Publications for Thyroid Gland Papillary Carcinoma

Articles related to Thyroid Gland Papillary Carcinoma:

(show top 50) (show all 6980)
# Title Authors PMID Year
1
Overexpression of long noncoding RNA SLC26A4-AS1 inhibits the epithelial-mesenchymal transition via the MAPK pathway in papillary thyroid carcinoma. 61
31556116 2020
2
Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma. 61
31953163 2020
3
microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signaling pathway. 61
31565805 2020
4
LncRNA PTCSC3 inhibits the proliferation, invasion and migration of cervical cancer cells via sponging miR-574-5p. 61
31587336 2020
5
Micro-FTIR spectroscopy as robust tool for psammoma bodies detection in papillary thyroid carcinoma. 61
31887679 2020
6
Risk factors for right paraesophageal lymph node metastasis in papillary thyroid carcinoma: A meta-analysis. 61
31987575 2020
7
Effect of miR‑449a‑mediated Notch signaling pathway on the proliferation, apoptosis and invasion of papillary thyroid carcinoma cells. 61
31894345 2020
8
Utility of Activated Carbon Nanoparticle (CNP) During total Thyroidectomy for Clinically Nodal Positive Papillary Thyroid Carcinoma (PTC). 61
31399795 2020
9
Prognostic Value of Extranodal Tumor Extension in Papillary Thyroid Carcinoma: Proposal for Upstaging of Cases with Extranodal Tumor Extension. 61
31605175 2020
10
Nomogram based on shear-wave elastography radiomics can improve preoperative cervical lymph node staging for papillary thyroid carcinoma. 61
32027225 2020
11
Long noncoding RNA small nucleolar RNA host gene 12 promotes papillary thyroid carcinoma cell growth and invasion by targeting miR-16-5p. 61
31355416 2020
12
Upregulation of microRNA-143-3p induces apoptosis and suppresses proliferation, invasion, and migration of papillary thyroid carcinoma cells by targeting MSI2. 61
31738908 2020
13
The extent of lymph node yield in central neck dissection can be affected by preoperative and intraoperative assessment and alter the prognosis of papillary thyroid carcinoma. 61
31854077 2020
14
Long noncoding RNA SAMMSON promotes papillary thyroid carcinoma progression through p300/Sp1 axis and serves as a novel diagnostic and prognostic biomarker. 61
31478331 2020
15
miR-200b/c-RAP1B axis represses tumorigenesis and malignant progression of papillary thyroid carcinoma through inhibiting the NF-κB/Twist1 pathway. 61
31877303 2020
16
Suspicious ultrasound characteristics correlate with multiple factors that predict central lymph node metastasis of papillary thyroid carcinoma: Significant role of HBME-1. 61
31918249 2020
17
The most reliable time point for intact parathyroid hormone measurement to predict hypoparathyroidism after total thyroidectomy with central neck dissection to treat papillary thyroid carcinoma: a prospective cohort study. 61
31620890 2020
18
Utility of Tumor Capsule Thickness as a Predictor of Invasion in Encapsulated Follicular Variant of Papillary Thyroid Carcinoma and a Diagnostic Tool for Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features. 61
31256687 2020
19
Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents. 61
31576470 2020
20
Glyco-CPLL: An Integrated Method for In-Depth and Comprehensive N-Glycoproteome Profiling of Human Plasma. 61
31860302 2020
21
Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma. 61
31821724 2020
22
LncRNA PTCSC3 Is a Biomarker for the Treatment and Prognosis of Gastric Cancer. 61
31702383 2020
23
Invasiveness and Metastatic Aggressiveness in Small Differentiated Thyroid Cancers: Demography of Small Papillary Thyroid Carcinomas in the Swedish Population. 61
31834455 2020
24
A Novel Technique for Performing Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA): A Single-port Platform. 61
31790081 2020
25
Choroidal metastases as initial manifestation of a papillary thyroid carcinoma: A case report. 61
31759732 2020
26
Thyroid carcinomas that occur in familial adenomatous polyposis patients recurrently harbor somatic variants in APC, BRAF, and KTM2D. 61
32024448 2020
27
Suspicious ultrasound and clinicopathological features of papillary thyroid carcinoma predict the status of TERT promoter. 61
32026251 2020
28
Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma. 61
32026467 2020
29
The effects of the genetic polymorphisms of antioxidant enzymes on susceptibility to papillary thyroid carcinoma. 61
32031754 2020
30
Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAFV600E mutation as biomarkers for papillary thyroid carcinoma. 61
32017063 2020
31
miR-125a-3p suppresses the growth and progression of papillary thyroid carcinoma cell by targeting MMP11. 61
31489990 2020
32
NR2F1-AS1 regulated miR-423-5p/SOX12 to promote proliferation and invasion of papillary thyroid carcinoma. 61
31692033 2020
33
Author Correction: Transcription Factor HOXA9 is Linked to the Calcification and Invasion of Papillary Thyroid Carcinoma. 61
32024936 2020
34
Tumor promoting effects of glucagon receptor: a promising biomarker of papillary thyroid carcinoma via regulating EMT and P38/ERK pathways. 61
31782107 2020
35
Predictive Risk-scoring Model For Central Lymph Node Metastasis and Predictors of Recurrence in Papillary Thyroid Carcinoma. 61
31959758 2020
36
1, 25-dihydroxy vitamin D3 inhibits Ras-MEK-ERK pathway and regulates proliferation and apoptosis of papillary thyroid carcinoma. 61
31982425 2020
37
Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma. 61
31922231 2020
38
Prognostic implications of the BRAF-V600E mutation in papillary thyroid carcinoma based on a new cut-off age stratification. 61
31897179 2020
39
MiR-145 inhibits the migration and invasion of papillary thyroid carcinoma cells through NF-κB pathway regulation. 61
31907977 2020
40
The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features. 61
31895498 2020
41
The optimal surgical approach for papillary thyroid carcinoma with pathological n1 metastases: An analysis from the SEER database. 61
30953386 2020
42
Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma with Biphasic Histology. 61
32015924 2020
43
Diallyl trisulfide, a H2 S donor, inhibits cell growth of human papillary thyroid carcinoma KTC-1 cells through a positive feedback loop between H2 S and cystathionine-gamma-lyase. 61
31984539 2020
44
Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma. 61
31935378 2020
45
Comparison of transoral endoscopic thyroidectomy vestibular approach, total endoscopic thyroidectomy via areola approach, and conventional open thyroidectomy: a retrospective analysis of safety, trauma, and feasibility of central neck dissection in the treatment of papillary thyroid carcinoma. 61
31346748 2020
46
Value of Qualitative and Quantitative Contrast-Enhanced Ultrasound Analysis in Preoperative Diagnosis of Cervical Lymph Node Metastasis From Papillary Thyroid Carcinoma. 61
31222782 2020
47
Sonographic features of follicular variant of papillary thyroid carcinoma (FV-PTC) and diagnostic performance of the 2017 ACR TI-RADS in FV-PTC. 61
31919771 2020
48
Downregulating integrin subunit alpha 7 (ITGA7) promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition. 61
31942970 2020
49
Relationship Between Morphologic Characteristics of Ultrasonic Calcification in Thyroid Nodules and Thyroid Carcinoma. 61
31582180 2020
50
Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial-mesenchymal transition. 61
31989658 2020

Variations for Thyroid Gland Papillary Carcinoma

Cosmic variations for Thyroid Gland Papillary Carcinoma:

9 (show top 50) (show all 3512)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149314757 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 15
2 COSM89410732 ZBTB2 thyroid,NS,carcinoma,papillary carcinoma c.1012C>G p.P338A 6:151366054-151366054 15
3 COSM101976985 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 15
4 COSM101980763 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 15
5 COSM91385851 WT1 thyroid,NS,carcinoma,papillary carcinoma c.698C>G p.S233W 11:32428568-32428568 15
6 COSM96873846 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 15
7 COSM88292485 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 15
8 COSM131082360 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 15
9 COSM131082578 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 15
10 COSM131089095 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 15
11 COSM131082573 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 15
12 COSM131083920 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1897G>T p.D633Y 14:81143955-81143955 15
13 COSM131087323 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 15
14 COSM87027692 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4433A>T p.D1478V 16:2084655-2084655 15
15 COSM87028962 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 15
16 COSM87049629 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4760G>A p.C1587Y 16:2086290-2086290 15
17 COSM94304986 TRRAP thyroid,NS,carcinoma,papillary carcinoma c.7726A>C p.T2576P 7:98971853-98971853 15
18 COSM99628948 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.925G>T p.E309* 15:43477623-43477623 15
19 COSM99620599 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.5480G>T p.G1827V 15:43409017-43409017 15
20 COSM87900604 TP53 thyroid,NS,carcinoma,papillary carcinoma c.637C>T p.R213* 17:7674894-7674894 15
21 COSM87899887 TP53 thyroid,NS,carcinoma,papillary carcinoma c.856G>A p.E286K 17:7673764-7673764 15
22 COSM87897687 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 15
23 COSM87913147 TP53 thyroid,NS,carcinoma,papillary carcinoma c.845G>A p.R282Q 17:7673775-7673775 15
24 COSM87903333 TP53 thyroid,NS,carcinoma,papillary carcinoma c.646G>A p.V216M 17:7674885-7674885 15
25 COSM87952319 TP53 thyroid,NS,carcinoma,papillary carcinoma c.670G>T p.E224* 17:7674861-7674861 15
26 COSM87935614 TP53 thyroid,NS,carcinoma,papillary carcinoma c.738G>A p.M246I 17:7674225-7674225 15
27 COSM87898723 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 15
28 COSM87912435 TP53 thyroid,NS,carcinoma,papillary carcinoma c.396G>C p.K132N 17:7675216-7675216 15
29 COSM87901016 TP53 thyroid,NS,carcinoma,papillary carcinoma c.734G>T p.G245V 17:7674229-7674229 15
30 COSM87897711 TP53 thyroid,NS,carcinoma,papillary carcinoma c.818G>A p.R273H 17:7673802-7673802 15
31 COSM87911941 TP53 thyroid,NS,carcinoma,papillary carcinoma c.749C>T p.P250L 17:7674214-7674214 15
32 COSM87967501 TP53 thyroid,NS,carcinoma,papillary carcinoma c.398T>C p.M133T 17:7675214-7675214 15
33 COSM87900303 TP53 thyroid,NS,carcinoma,papillary carcinoma c.638G>A p.R213Q 17:7674893-7674893 15
34 COSM87904588 TP53 thyroid,NS,carcinoma,papillary carcinoma c.374C>T p.T125M 17:7675995-7675995 15
35 COSM87905856 TP53 thyroid,NS,carcinoma,papillary carcinoma c.643A>G p.S215G 17:7674888-7674888 15
36 COSM87906968 TP53 thyroid,NS,carcinoma,papillary carcinoma c.833C>T p.P278L 17:7673787-7673787 15
37 COSM87899497 TP53 thyroid,NS,carcinoma,papillary carcinoma c.586C>T p.R196* 17:7674945-7674945 15
38 COSM87907024 TP53 thyroid,NS,carcinoma,papillary carcinoma c.799C>T p.R267W 17:7673821-7673821 15
39 COSM87898351 TP53 thyroid,NS,carcinoma,papillary carcinoma c.743G>A p.R248Q 17:7674220-7674220 15
40 COSM87898424 TP53 thyroid,NS,carcinoma,papillary carcinoma c.722C>T p.S241F 17:7674241-7674241 15
41 COSM87897883 TP53 thyroid,NS,carcinoma,papillary carcinoma c.659A>G p.Y220C 17:7674872-7674872 15
42 COSM87898714 TP53 thyroid,NS,carcinoma,papillary carcinoma c.844C>T p.R282W 17:7673776-7673776 15
43 COSM87898758 TP53 thyroid,NS,carcinoma,papillary carcinoma c.707A>G p.Y236C 17:7674256-7674256 15
44 COSM87898862 TP53 thyroid,NS,carcinoma,papillary carcinoma c.722C>G p.S241C 17:7674241-7674241 15
45 COSM87935575 TP53 thyroid,NS,carcinoma,papillary carcinoma c.528C>G p.C176W 17:7675084-7675084 15
46 COSM87899771 TP53 thyroid,NS,carcinoma,papillary carcinoma c.716A>C p.N239T 17:7674247-7674247 15
47 COSM88143179 TP53 thyroid,NS,carcinoma,papillary carcinoma c.96+1G>C p.? 17:7676381-7676381 15
48 COSM87901134 TP53 thyroid,NS,carcinoma,papillary carcinoma c.417G>C p.K139N 17:7675195-7675195 15
49 COSM87899842 TP53 thyroid,NS,carcinoma,papillary carcinoma c.584T>C p.I195T 17:7674947-7674947 15
50 COSM87985318 TP53 thyroid,NS,carcinoma,papillary carcinoma c.691A>G p.T231A 17:7674272-7674272 15

Expression for Thyroid Gland Papillary Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Papillary Carcinoma.

Pathways for Thyroid Gland Papillary Carcinoma

Pathways related to Thyroid Gland Papillary Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 MIR222 MIR221 MIR181A1 MIR17
2 11.85 MIRLET7E MIR9-1 MIR30A MIR25 MIR222 MIR221
3 11.16 MIR25 MIR222 MIR221 MIR181A1
4 11.01 MIR9-1 MIR222 MIR221 MIR199A1 MIR181A1 MIR146B

GO Terms for Thyroid Gland Papillary Carcinoma

Cellular components related to Thyroid Gland Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 MIRLET7E MIR574 MIR486-1 MIR30A MIR25 MIR222

Biological processes related to Thyroid Gland Papillary Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.87 MIR17 MIR146B MIR146A MIR140
2 positive regulation of protein kinase B signaling GO:0051897 9.86 RET MIR222 MIR221 MIR199A1
3 cellular response to hypoxia GO:0071456 9.8 MIR17 MIR146A MIR140
4 negative regulation of inflammatory response GO:0050728 9.78 MIR222 MIR221 MIR181A1 MIR146A
5 positive regulation of blood vessel endothelial cell migration GO:0043536 9.72 MIR499A MIR30A MIR221
6 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.71 MIR30A MIR222 MIR221
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.7 MIR221 MIR146B MIR146A
8 negative regulation of interleukin-6 production GO:0032715 9.67 MIR181A1 MIR146A MIR140
9 negative regulation of cholesterol efflux GO:0090370 9.62 MIR144 MIR130B
10 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.61 MIR199A1 MIR17
11 negative regulation of toll-like receptor 4 signaling pathway GO:0034144 9.61 MIR146A MIR140
12 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.6 MIR199A1 MIR17
13 positive regulation of axon regeneration GO:0048680 9.59 MIR222 MIR221
14 negative regulation by host of viral genome replication GO:0044828 9.58 MIR222 MIR221
15 regulation of toll-like receptor signaling pathway GO:0034121 9.58 MIR146B MIR146A
16 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.56 MIR499A MIR222 MIR221 MIR17
17 miRNA mediated inhibition of translation GO:0035278 9.56 MIR9-1 MIR499A MIR30A MIR222 MIR221 MIR181A1
18 gene silencing by miRNA GO:0035195 9.53 MIRLET7E MIR9-1 MIR499A MIR30A MIR25 MIR222
19 negative regulation of cell adhesion molecule production GO:0060354 9.51 MIR222 MIR221
20 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.5 MIR222 MIR221 MIR140
21 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.46 MIR222 MIR221
22 positive regulation of Schwann cell migration GO:1900149 9.43 MIR222 MIR221
23 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.4 MIR222 MIR221
24 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.37 MIR222 MIR221
25 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.33 MIR222 MIR221 MIR146A

Molecular functions related to Thyroid Gland Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.53 MIRLET7E MIR9-1 MIR499A MIR30A MIR25 MIR222

Sources for Thyroid Gland Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....